SMR Congress | Conference

Understanding BRAF Resistance Critical to Advancing Melanoma Care

November 21st 2015

Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.

Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated Melanoma

November 21st 2015

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

November 21st 2015

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.

James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations

November 20th 2015

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

November 20th 2015

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

Nivolumab Survival Benefit Sustained in Long-Term Melanoma Data

November 20th 2015

Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.

Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma

November 20th 2015

With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.

Dr. Michael Krauthammer on NF1 Mutations in Melanoma

November 20th 2015

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma

November 19th 2015

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Researchers Seek to Improve Responses With Checkpoint Inhibitors

November 19th 2015

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

Dr. Sancy Leachman on Helping Patients Identify Melanoma Recurrences

November 19th 2015

Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.

Sheri Holmen on Understanding Drivers of Melanoma Metastasis

November 19th 2015

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

New Treatments for Novel Targets Next Step in Immuno-Oncology Revolution

November 19th 2015

There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.